El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by (c)  Alonso-Navarro Rodrigo et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224863

Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Background Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to remdesivir. Methods We conducted a retrospective multicentric study analysing all patients admitted with COVID-19 in 9 Spanish hospitals who received treatment with remdesivir in October 2020. The main outcome was the need of ICU admission after 24 h of the first dose of remdesivir. Results In our cohort of 497 patients, the median of days from symptom onset to remdesivir was 5 days, and 70 of them (14.1%) were later admitted into ICU. The clinical outcomes associated with ICU admission were days from symptoms onset (5 vs. 6; p = 0.023), clinical signs of severe disease (respiratory rate, neutrophil count, ferritin levels and very-high mortality rate in SEIMC-Score) and the use of corticosteroids and anti-inflammatory drugs before ICU. The only variable significatively associated with risk reduction in the Cox-regression analyses was ≤ 5 days from symptoms onset to RDV (HR: 0.54, CI95%: 0.31–0.92; p = 0.024). Conclusion For patients admitted to the hospital with COVID-19, the prescription of remdesivir within 5 days from symptoms onset diminishes the need of ICU admission.

Matèries (anglès)

Citació

Citació

ALONSO NAVARRO, Rodrigo, RAMÍREZ, Margarita, MASIÁ, Mar, PAREDES, Roger, MONTEJANO, Rocío, POVAR ECHEVERRIA, Marina, CARRATALÀ, Jordi, SALAVERT, Miguel, BERNAL, Enrique, DUEÑAS, Carlos, FLORES, Juan, FANJUL, Francisco, GUTIÉRREZ, Isabel, RICO, Verónica, MATEU, Lourdes, CADIÑANOS, Julen, BERENGUER BERENGUER, Juan, SORIANO, Alex. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses. _BMC Infectious Diseases_. 2023. Vol. 23, núm. 1. [consulta: 3 de gener de 2026]. ISSN: 1471-2334. [Disponible a: https://hdl.handle.net/2445/224863]

Exportar metadades

JSON - METS

Compartir registre